Prosecution Insights
Last updated: August 18, 2026

Xeris Pharmaceuticals Inc.

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
2
Medium (67%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (67%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
33% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BRADLEY, CHRISTINA 1 62.9% +33.0%
KWON, JOHN SEUNGJAI 1 45.1% +20.2%
VARGAS, ANNA ELIZABETH 1 59.7% +54.1%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
16630774 METHODS FOR TREATING CONGENITAL HYPERINSULINISM VARGAS, ANNA ELIZABETH

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18617015 STABLE SUSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME BRADLEY, CHRISTINA
17930857 INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF KWON, JOHN SEUNGJAI
16630774 METHODS FOR TREATING CONGENITAL HYPERINSULINISM VARGAS, ANNA ELIZABETH

Top Art Units

Art UnitApps
1654 1
1615 1
3783 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18617015 STABLE SUSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME BRADLEY, CHRISTINA 1654 §103 Final Rejection Pending Mar 26, 2024
17930857 INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF KWON, JOHN SEUNGJAI 1615 §103 Non-Final OA Pending Sep 09, 2022
16630774 METHODS FOR TREATING CONGENITAL HYPERINSULINISM VARGAS, ANNA ELIZABETH 3783 §103§112 Final Rejection Pending Jan 13, 2020

Managing Xeris Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month